Abstract
In This Issue...
The market for multiple sclerosis (MS) therapies is dominated by a handful of
key players-Biogen Idec, Serono, Schering AG, and Teva-who produce premium
priced therapies including interferon-beta (Biogen Idec' s Avonex, Serono' s
Rebif, and Schering AG' s Betaseron) and Teva' s Copaxone. Despite the
commercial success of existing drugs, a high level of unmet clinical need
exists, providing ample market opportunity for new treatments that demonstrate
improved efficacy, tolerability, and convenience in comparison to currently
available treatments.
Questions Answered in This Report
- Competitive dynamics: Market-leading recombinant interferon-beta
therapies, such as Biogen Idec' s Avonex, Serono' s Rebif, and Schering AG' s
Betaseron, are involved in an intensely competitive arena-from both a
within-class perspective and from the other leading MS agent, Teva' s altered
peptide ligand, Copaxone. How have the leading competitors positioned
their brands for success? Which interferon-beta drugs will continue to
succeed in the market?
- Market dynamics: The introduction of guidelines for the approval of
biosimilar medicinal products in Europe will dramatically affect the market
for recombinant interferon-beta. When will biosimilar interferon-beta
launch in the major markets? What level of uptake will biosimilars experience
and which branded drugs will be most affected?
- Brand dynamics: Following its withdrawal over safety concerns,
Biogen Idec' s Tysabri has relaunched following an in-depth review of the drug
by US and European regulators. How will Tysabri' s availability impact the
MS market? What effect will safety concerns have on Tysabri' s commercial
success?
- Key events: Few new drugs have been successfully developed for the
treatment of MS in recent years, leaving the market to established
competitors. What new drugs are forecast to enter the MS market between
2005 and 2010 and when will they launch? What products are being developed in
the major MS competitors' pipelines?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Market Analysis: Annualized 5-year sales forecasts presented by
region, drug class, molecule, and brand for 2005 to 2010, including a
breakdown of branded versus generic sales for each market and the impact of
key events during the forecast period. Annualized forecast of total prevalent
and diagnosed cases for each of the major markets from 2005 to 2010.
- Company Analysis: Detailed discussion of major competitors
including Biogen Idec, Teva Pharmaceuticals, Serono, and Schering AG.
Includes analysis of each company' s MS product portfolio, strategic
positioning, licensing strategy, post-marketing clinical trials, and
development pipeline.
- Brand Analysis: The report features an in-depth discussion of
leading brands in the MS market, including approval history, sales and market
position, SWOT analysis, annualized sales forecast, promotional efforts, and
on-going life cycle management initiatives.
|
Related Report
|
View Cart
